AskBio to Present AAV Gene Therapy Advances at ESGCT 2025 Meeting
核心洞察
AskBio will deliver six presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting in Seville, Spain, showcasing advances in AAV (搜索)-based gene therapies and manufacturing technologies.
The presentations will cover the company's clinical pipeline targeting debilitating diseases including congestive heart failure (搜索), Parkinson's disease (搜索), and muscular dystrophy conditions.
AskBio's ambitious portfolio aims to deliver breakthrough treatments that could benefit more than 35 million patients worldwide across multiple therapeutic areas.
AskBio Inc., a gene therapy company wholly owned by Bayer AG, will present six research presentations at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Meeting taking place October 7-10, 2025, in Seville, Spain. The presentations will highlight progress in the company's adeno-associated virus (AAV (搜索)) therapy pipeline and advancements in manufacturing technologies.
"ESGCT brings together leading researchers, clinicians, and industry experts to drive forward the field of gene and cell therapy and, as a company with a significant presence both in U.S. and Europe, this meeting is a special opportunity for us to interact with these prestigious stakeholders," said Gustavo Pesquin, Chief Executive Officer of AskBio.
Clinical Pipeline and Manufacturing Focus
The presentations will span discovery, preclinical, and clinical stages of AskBio's development programs. Pesquin emphasized the company's commitment to delivering therapies at scale through robust production and translational excellence, aiming to "translate hope into real-world impact for patients facing serious rare and more common diseases."
AskBio's presentation schedule includes one oral presentation and five poster presentations. The oral presentation, titled "Delivery technologies: A Strategic Platform Roadmap for Commercializing Gene Therapy," will be delivered by Cesar Trigueros from Viralgen (搜索) on Wednesday, October 8, from 6:00-7:30 p.m.
Therapeutic Areas and Patient Impact
The company continues to develop AAV (搜索)-based therapies targeting some of the world's most debilitating diseases, including congestive heart failure (搜索), limb-girdle muscular dystrophy (搜索), multiple system atrophy (搜索), Parkinson's disease (搜索), and Pompe disease (搜索). By targeting diseases across several therapeutic areas, AskBio aims to deliver breakthrough treatments that could benefit more than 35 million patients worldwide.
Manufacturing Innovation
Several presentations will focus on manufacturing advancements, including optimized adenovirus helper plasmids for enhanced AAV (搜索) vector production, development of antibody-escaping AAV vectors, and integration of Raman spectroscopy with genome-scale modeling to enhance upstream manufacturing processes.
AskBio maintains a clinical-stage pipeline with investigational therapeutics across cardiovascular, central nervous system, and neuromuscular conditions. The company's end-to-end gene therapy platform includes Pro10™ technology, designed to make gene therapies more accessible through affordable research and commercial-grade manufacturing.
Company Background
As a fully integrated gene therapy company with over 900 employees across five countries, AskBio holds more than 600 patents and patent applications in areas such as AAV (搜索) production and chimeric capsids. The company has generated hundreds of proprietary capsids and promoters, several of which have entered preclinical and clinical testing.
Viralgen (搜索), AskBio's subsidiary founded in 2017, operates as a contract development and manufacturing organization specializing in large-scale production of current good manufacturing practice (cGMP) AAV (搜索) for gene therapies. Located in San Sebastian, Spain, the facility features three cGMP suites with 2,000-liter capacities each, certified by the AEMPS/EMA.